GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (LTS:0IFK) » Definitions » Price-to-Free-Cash-Flow

Editas Medicine (LTS:0IFK) Price-to-Free-Cash-Flow : N/A (As of Dec. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Editas Medicine Price-to-Free-Cash-Flow?

As of today (2024-12-15), Editas Medicine's share price is $1.43. Editas Medicine's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.33. Hence, Editas Medicine's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Editas Medicine's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, Editas Medicine's highest Price-to-Free-Cash-Flow Ratio was 206.24. The lowest was 20.87. And the median was 53.68.

LTS:0IFK's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.18
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Editas Medicine's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.67. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.33.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -17.00% per year.

During the past 11 years, Editas Medicine's highest 3-Year average Free Cash Flow per Share Growth Rate was 23.60% per year. The lowest was -123.70% per year. And the median was -33.40% per year.


Editas Medicine Price-to-Free-Cash-Flow Historical Data

The historical data trend for Editas Medicine's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Price-to-Free-Cash-Flow Chart

Editas Medicine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Editas Medicine Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Editas Medicine's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Editas Medicine's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Price-to-Free-Cash-Flow falls into.



Editas Medicine Price-to-Free-Cash-Flow Calculation

Editas Medicine's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.43/-2.328
=N/A

Editas Medicine's Share Price of today is $1.43.
Editas Medicine's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.33.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Editas Medicine  (LTS:0IFK) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Editas Medicine Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines